Sun Pharma reported a 36% decline in Q2FY27 net profit to Rs 1,989 crore due to exceptional litigation and acquisition-related costs. Revenue grew 11.8%, supported by strong domestic and emerging market sales, while US formulations weakened.
Sun Pharma reported a 36% decline in Q2FY27 net profit to Rs 1,989 crore due to exceptional litigation and acquisition-related costs. Revenue grew 11.8%, supported by strong domestic and emerging market sales, while US formulations weakened.
<iframe src="https://hindustansphere.com/embed/cluster/26bdf9324c5704851c904af5dc86ebbb1d121f65" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Sun Pharma Q2 profit falls 36% as litigation costs hit earnings"></iframe>
